doi
biorxiv
preprint
compon
allan
met
contrast
variabl
close
untreat
control
fig
extend
data
fig
drug
synergi
lifespan
extens
next
determin
effect
differ
drug
combin
lifespan
nematod
began
met
rap
due
translat
import
human
howev
rap
combin
met
optim
dose
show
benefit
lifespan
extend
data
fig
p
carri
addit
trial
explor
possibl
combin
optim
halfoptim
dose
met
rap
extend
data
fig
combin
rap
met
halfoptim
dose
result
extens
maximum
lifespan
fig
extend
data
fig
result
mean
lifespan
extens
extend
data
weak
benefit
combin
met
rap
consist
result
mice
exist
evid
suggest
addit
figur
lifespan
comparison
tripl
combin
supplementari
figur
raprifpsora
show
benefit
compar
dual
synergist
combin
raprif
rifpsora
b
raprifmet
toxic
compar
raprif
worm
per
condit
c
rappsoraallan
show
benefit
compar
singl
drug
constitu
raprifallan
rifpsoraallan
result
signific
lifespan
extens
compar
raprif
rifpsora
respect
logrank
proper
adjust
e
mean
f
maximum
lifespan
figur
show
monoton
increas
singl
drug
doubl
tripl
combin
oneway
anova
bonferroni
multipl
comparison
doi
biorxiv
preprint
ejs
c
et
al
collisioninduc
dissoci
pathway
yeast
sphingolipid
molecular
profil
total
lipid
extract
studi
quadrupol
tof
linear
ion
orbitrap
mass
spectrometri
summari
pharmacolog
intervent
target
human
age
would
extend
individu
healthspan
result
dramat
econom
benefit
rapidli
age
societi
worldwid
intervent
contempl
need
compris
drug
efficaci
given
adult
extens
human
safeti
data
avail
show
dramat
lifespan
extens
achiev
celegan
target
multipl
evolutionarili
conserv
age
pathway
use
drug
alreadi
human
use
target
multipl
synergist
age
pathway
abl
slow
age
rate
doubl
lifespan
improv
healthspan
minim
development
fit
off
moreov
establish
synergist
benefit
background
impli
involv
tgf
igf
pathway
synergi
employ
lipidom
transcriptom
analysi
found
lipid
metabol
affect
result
increas
monounsatur
fatti
acid
mufa
decreas
membran
peroxid
index
best
drug
combin
show
conserv
lifespan
extens
fruit
fli
best
knowledg
largest
lifespan
effect
ever
report
adultonset
drug
treatment
c
elegan
drugrepurpos
approach
use
drug
alreadi
approv
human
target
multipl
conserv
age
pathway
simultan
could
lead
intervent
prevent
agerel
diseas
overal
frailti
rapidli
age
popul
import
find
biogerontolog
evolutionarili
conserv
pathway
regul
lifespan
model
organ
mutat
affect
pathway
often
extend
lifespan
combin
differ
genet
mutat
result
synergist
lifespan
extens
contrast
effect
pharmacolog
intervent
typic
much
weaker
even
target
pathway
genet
synergi
suggest
potenti
strategi
design
novel
pharmacolog
intervent
simultan
target
multipl
evolutionarili
conserv
age
pathway
date
littl
data
synergist
effect
pharmacolog
intervent
lifespan
report
vivo
approach
design
novel
multidrug
age
intervent
show
multidrug
intervent
leverag
pathway
synergi
maxim
effect
size
minim
side
effect
detriment
development
tradeoff
target
distinct
interact
age
pathway
ultim
aim
design
pure
pharmacolog
onset
intervent
lifespan
efficaci
similar
better
canon
age
mutat
due
lack
gener
accept
biolog
marker
age
lifespan
studi
current
way
test
efficaci
age
intervent
therefor
develop
candid
drug
combin
shortliv
model
organ
nematod
caenorhabd
elegan
use
approach
identifi
two
tripl
drug
combin
extend
lifespan
healthspan
extent
greater
previous
report
pharmacolog
intervent
c
elegan
synergist
drug
combin
show
effect
size
compar
classic
age
mutat
avoid
tradeoff
associ
find
intervent
actual
increas
marker
perform
slow
biolog
age
rate
moreov
identifi
tgf
key
contributor
requir
pathway
mediat
synergist
effect
also
find
worm
treat
synergist
drug
combin
higher
mufa
pufa
ratio
decreas
membran
lipid
peroxid
index
final
confirm
synergist
effect
also
present
fruit
fli
drosophila
melanogast
tabl
chose
target
amp
activ
protein
kinas
ampk
mammalian
target
rapamycin
mtor
calor
restrict
cr
cjun
ntermin
kinas
jnk
mitohormesismitochondri
metabol
primari
longev
regulatori
pathway
pathway
identifi
drug
druglik
molecul
report
extend
lifespan
least
one
common
model
organ
nematod
fruit
fli
mice
interest
drug
might
eventu
test
human
favor
drug
report
efficaci
mammal
alreadi
approv
human
use
base
criteria
initi
select
eleven
candid
drug
supplementari
tabl
ad
allantoin
studi
base
report
show
lifespan
effect
c
elegan
transcript
analysi
suggest
mode
action
unusu
distinct
compound
tabl
transcript
analys
reveal
signific
overlap
affect
gene
also
identifi
set
gene
uniqu
individu
compound
fig
met
show
signific
overlap
drug
smallest
uniqu
set
almost
gene
affect
met
psora
also
affect
least
one
drug
set
fig
allan
caus
fewer
geneexpress
chang
overal
compound
gene
affect
allan
uniqu
affect
drug
gene
affect
met
uniqu
fig
systemat
determin
efficaci
ten
possibl
pair
five
candid
drug
extend
data
fig
trial
defin
synergi
base
higher
singl
activ
hsa
model
drug
combin
consid
synergist
combinatori
effect
significantli
larger
combin
singl
drug
effect
ideal
concentr
combin
use
definit
identifi
two
synergist
combin
ten
pair
test
fig
sever
drug
test
previous
report
cr
mimet
therefor
test
synergist
combin
constitu
compound
c
elegan
model
cr
mutant
found
rif
among
singl
drug
treatment
extend
lifespan
tabl
first
explor
transcriptom
data
chang
might
affect
lipid
composit
found
synergist
drug
combin
inde
result
signific
regul
c
elegan
master
transcript
factor
control
sever
lipogen
gene
gene
code
desaturas
respons
mufa
synthesi
fig
e
employ
msbase
lipidom
assay
determin
chang
lipid
composit
might
result
drug
treatment
worm
expos
synergist
drug
combin
signific
rise
tag
reserv
lifespan
optim
best
health
categori
nematod
expos
rifpsoraallan
raprifallan
spent
respect
alreadi
extend
lifespan
optim
health
fig
extend
data
mean
health
span
significantli
extend
absolut
rel
term
inde
half
treat
anim
still
optim
health
even
last
control
anim
die
fig
extend
data
fig
surprisingli
anim
treat
raprifallan
rifpsoraallan
also
perform
significantli
better
spontan
movement
assay
control
anim
age
fact
old
treat
anim
day
age
show
perform
assay
indistinguish
young
day
control
fig
moreov
treat
anim
experienc
improv
resist
heat
oxid
stress
paraquat
assay
figur
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
limit
detect
tradeoff
also
improv
health
span
increas
stress
resist
even
increas
physic
perform
observ
rais
import
question
lifespan
benefit
due
actual
delay
biolog
age
rate
rate
age
express
mortal
rate
doubl
time
mrdt
determin
mrdt
anim
expos
synergist
drug
combin
use
survcurv
found
mrdt
significantli
longer
rifpsoraallan
treat
anim
compar
control
mrdt
control
day
rifpsoraallan
day
p
valu
initi
mortal
rate
significantli
lower
synergist
note
cohort
size
fli
smaller
worm
reoptim
drug
fli
experi
howev
data
confirm
detect
synergi
appear
evolutionari
conserv
target
multipl
overlap
age
longevityrel
pathway
succeed
design
synergist
pharmacolog
intervent
even
appli
anim
adult
age
doubl
healthi
lifespan
c
elegan
effect
size
compar
classic
age
mutat
best
knowledg
largest
report
adultonset
pharmacolog
intervent
howev
unlik
age
mutat
detect
limit
detriment
evolutionari
fit
tradeoff
associ
lifespan
extens
drug
synergi
particular
detect
decreas
oxygen
consumpt
total
fecund
latter
result
consist
previou
studi
show
benefit
adultonset
intervent
use
resveratrol
without
reduc
fecund
data
suggest
signific
control
fig
mortal
analysi
suggest
one
synergist
drug
treatment
slow
basic
biolog
age
rate
extend
data
fig
test
evolutionari
conserv
determin
lifespan
benefit
fruit
fli
drosophila
melanogast
confirm
qualit
conserv
two
four
synergist
drug
combin
nematod
evolutionarili
distant
fruit
fli
mammal
make
mechan
pathway
conserv
fli
nematod
ancient
trace
synergi
back
common
ancestor
three
clade
explor
mechan
synergist
lifespan
benefit
carri
epistasi
experi
transcriptom
analysi
find
igffoxo
well
tgf
pathway
involv
synergist
lifespan
extens
fig
p
valu
p
valu
p
valu
tabl
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
extend
data
figur
figur
health
span
tradeoff
supplementari
figur
drug
synergi
extend
reproduct
period
worm
per
condit
b
heat
shock
stress
rifpsoraallan
improv
heat
shock
stress
resist
young
day
worm
older
day
worm
c
health
span
score
differ
age
age
young
old
drug
synergi
treat
worm
better
health
span
respect
age
match
control
p
p
p
ccbynd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
extend
data
figur
b
c
figur
drug
synergi
slow
mortal
rate
delay
death
incid
rate
dual
tripl
synergist
combin
slow
rate
mortal
wild
type
worm
experi
bristol
wildtyp
mutant
nematod
grown
maintain
nematod
growth
medium
ngm
agar
plate
use
e
coli
bacteria
food
sourc
unless
otherwis
note
plate
pour
dri
seal
store
e
coli
spot
plate
previou
even
allow
dri
compound
treatment
agar
plate
prepar
batch
ngm
agar
treatment
plate
supplement
respect
compound
vehicl
control
fresh
plate
prepar
everi
week
follow
worm
strain
use
wild
type
strain
provid
takao
inou
strain
obtain
caenorhabd
genet
center
cgc
bacteri
wavelength
bacteri
stock
dilut
frozen
c
ngm
plate
seed
bacteria
use
lifespan
assay
without
incub
drug
vehicl
ad
bacteria
addit
ad
ngm
seed
determin
lifespan
determin
c
elegan
lifespan
nematod
age
synchron
bleach
allow
hatch
young
adult
worm
per
condit
transfer
cultur
plate
worm
transfer
fresh
plate
everi
day
progeni
product
ceas
everi
two
three
day
afterward
worm
die
number
worm
aliv
determin
everi
day
dead
worm
remov
plate
worm
consid
dead
touchprovok
movement
observ
anim
crawl
plate
exhibit
extrud
intern
organ
display
egg
lay
defect
subsequ
hatch
larva
insid
mother
censor
lifespan
assay
blind
repeat
least
two
time
graph
pad
prism
softwar
use
calcul
mean
adult
lifespan
perform
statist
analysi
signific
use
logrank
test
mantelcox
compound
identif
valid
primari
screen
first
identifi
wellcharacter
age
regulatori
pathway
extend
data
next
identifi
drug
druglik
molecul
known
target
select
pathway
extend
lifespan
common
age
model
organ
worm
fli
mice
compound
report
target
known
age
pathway
yet
experiment
valid
lifespanextend
also
includ
approach
culmin
identif
candid
drug
extend
data
primari
efficaci
confirm
term
lifespan
c
elegan
initi
screen
compound
effect
lifespan
wild
type
nematod
conduct
use
standard
condit
presenc
antibiot
streptomycin
drug
druglik
molecul
five
result
reproduc
lifespan
extens
lab
fig
compound
pass
primari
screen
doserespons
assay
carri
establish
ideal
dose
maximum
effect
size
ccbynd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
efficaci
individu
drug
tripl
drug
combin
test
combin
effect
sum
effect
best
pair
three
drug
mortal
experiment
determin
mortal
rate
one
power
intervent
rifpsoraallan
use
larg
cohort
worm
per
condit
dead
worm
count
everi
day
worm
dead
raprifallan
combin
lifespan
data
import
survcurv
mortal
analysi
maximum
lifespan
comparison
use
gompertz
surviv
model
determin
initi
mortal
rate
mortal
rate
doubl
time
use
follow
equat
freshli
prepar
bacteria
e
coli
spot
cm
ngm
agar
plate
previou
even
allow
dri
synchron
young
adult
worm
transfer
fresh
plate
maintain
synchron
popul
fudr
ad
ngm
media
two
day
treatment
drug
vehicl
adult
worm
wash
plate
ml
tube
wash
sever
time
clear
solut
indic
bacteria
complet
remov
obtain
clean
worm
pellet
frozen
use
rna
extract
total
rna
isol
use
qiagen
rnaeasi
micro
kit
qiagen
hilden
germani
follow
standard
protocol
afterward
rna
quantifi
photometr
nanodrop
store
c
use
integr
total
rna
measur
agil
bioanalyz
librari
prepar
amount
total
rna
per
sampl
process
use
illumina
rna
sampl
prep
kit
follow
manufactur
instruct
illumina
san
diego
ca
usa
singl
drug
process
togeth
multiplex
onto
one
lane
minim
batch
effect
differ
drug
combin
process
two
multiplex
lane
total
ran
three
lane
parallel
sampl
untreat
control
lane
librari
sequenc
use
illumina
sequenc
platform
illumina
san
diego
ca
usa
pair
end
read
approach
read
length
nucleotid
sequenc
data
extract
fastq
format
rnaseq
read
sampl
map
refer
c
elegan
transcriptom
kallisto
use
bootstrap
sampl
sequenc
base
bia
correct
estim
count
import
kallisto
r
environ
summar
genelevel
use
tximport
packag
packag
use
identifi
differenti
express
gene
deg
analysi
correct
batch
effect
applic
signific
threshold
correct
multipl
hypothesi
test
independ
hypothesi
weight
ihw
packag
pca
plot
graph
pcaexplor
packag
rlog
transform
data
ccbynd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
